Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04384484 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
A Phase 3 study of Refractory Diffuse Large B-Cell Lymphoma and Relapsed Diffuse Large B-cell Lymphoma, sponsored by ADC Therapeutics S.A..
- Active
- Registry status
- Phase 3
- Development phase
- 440
- Enrollment target
- 20
- Study locations
NCT04384484: Active Phase 3 study of Refractory Diffuse Large B-Cell Lymphoma and Relapsed Diffuse Large B-cell Lymphoma, sponsored by ADC Therapeutics S.A..
NCT04384484 is a Phase 3 study of Refractory Diffuse Large B-Cell Lymphoma and Relapsed Diffuse Large B-cell Lymphoma that is active but no longer recruiting, run by ADC Therapeutics S.A.. The registered enrollment target is 440 participants, above the 52-participant average among 37 other Refractory Diffuse Large B-Cell Lymphoma trials with a reported enrollment target (746% higher). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04384484, a Phase 3 study of Refractory Diffuse Large B-Cell Lymphoma and Relapsed Diffuse Large B-cell Lymphoma, is active but no longer recruiting, sponsored by ADC Therapeutics S.A..
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 440 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy of loncastuximab tesirine (ADCT-402) combined with rituximab compared to standard immunochemotherapy.
Conditions Studied
Interventions
- DRUG Oxaliplatin
- DRUG Rituximab
- DRUG Gemcitabine
- DRUG Loncastuximab Tesirine
Study Locations (20)
Other
- Algemeen Ziekenhuis Sint-Jan Brugge-Oostende - Campus Sint-Jan - Bruges
- Cliniques Universitaires Saint-Luc - Brussels
- Centre Hospitalier Universitaire Universite Catholique de Louvain - Namur
- Algemeen Ziekenhuis Delta - Campus Rumbeke - Roeselare
California
- University of California San Diego Moores Cancer Center - La Jolla
- Redlands Community Hospital - Redlands
- The Oncology Institute of Hope and Innovation - Whittier
Buenos Aires
- Clinica Adventista Belgrano - Belgrano
- Clínica de Nefrología, Urología y Enfermedades Cardiovasculares S.A. - Santa Fe
Florida
- Baptist MD Anderson Cancer Center - Jacksonville
Iowa
- UnityPoint Health - Iowa Oncology Research Association (IORA) - Des Moines
Kentucky
- Norton Cancer Institute - Louisville
Nevada
- Comprehensive Cancer Centers of Nevada - Henderson - Las Vegas
Oregon
- Kaiser Permanente Interstate Medical Office Central - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 440 participants |
| Start Date | 2020-09-16 |
| Est. Completion | 2028-06-30 |
| Phase | Phase 3 |
What the registry record for NCT04384484 still lists
NCT04384484 is an interventional study that assigns participants to a tested intervention. The registered 440 participants enrollment target is mid-sized for trials with a published cap, above the 52-participant average among 37 other Refractory Diffuse Large B-Cell Lymphoma trials with a reported enrollment target (746% higher).
The record links to 2 conditions, with Refractory Diffuse Large B-Cell Lymphoma appearing as the primary indexed condition, and to 4 interventions - of which Oxaliplatin is the first listed.
NCT04384484 names 20 study sites across 14 states, led by Other, California, Buenos Aires.
Frequently Asked Questions
What is clinical trial NCT04384484 about?
NCT04384484 is a clinical study titled "Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma". The purpose of this study is to evaluate the efficacy of loncastuximab tesirine (ADCT-402) combined with rituximab compared to standard immunochemotherapy.
What is the current status of trial NCT04384484?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 440 participants. The study started on 2020-09-16. Estimated completion is 2028-06-30.
What conditions does trial NCT04384484 study?
This clinical trial studies the following conditions: Refractory Diffuse Large B-Cell Lymphoma, Relapsed Diffuse Large B-cell Lymphoma.
What interventions are being tested in trial NCT04384484?
The interventions under investigation include: Oxaliplatin (DRUG), Rituximab (DRUG), Gemcitabine (DRUG), Loncastuximab Tesirine (DRUG).
Who is sponsoring clinical trial NCT04384484?
This trial is sponsored by ADC Therapeutics S.A., which has 18 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04384484 being conducted?
This trial has 20 study locations across California, Florida, Iowa, Kentucky, Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Refractory Diffuse Large B-Cell Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04384484's enrollment target sits among peer trials
440 1st of 37 higher than 37 of 37 other Refractory Diffuse Large B-Cell Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Refractory Diffuse Large B-Cell Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
RECRUITING · Phase 2
-
Fludarabine and Cyclophosphamide With or Without Rituximab Before CD19 Chimeric Antigen Receptor T Cells for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
RECRUITING · Phase 1
-
Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T
RECRUITING · Phase 2
-
Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma
RECRUITING · Phase 1
-
Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia
RECRUITING · Phase 2
-
Odronextamab for the Treatment of Relapsed and Refractory Diffuse Large B-cell Lymphoma Before and After Chimeric Antigen Receptor T-cell Therapy
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05114538 · 440 participants · NA
Improving the Part C Early Intervention Service Delivery System for Children with ASD
- NCT05117619 · 440 participants · NA
The HOME Program for Individuals With Traumatic Brain Injury and Family Members
- NCT05602194 · 440 participants · Phase 3
Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma
- NCT05624879 · 440 participants · NA
Accelerated Resolution Therapy for Early Maladaptive Grief
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI